Canaccord Genuity Reiterates Buy on Radius Health (RDUS) Following ASBMR Presentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- 'No panic anywhere' may be the problem, BofA strategists warn
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Radius Health (RDUS) Trades to Session Lows
October 12, 2015 2:41 PM EDTRadius Health (Nasdaq: RDUS) is moving to session lows Monday after the company announced the... More
Radius Health (RDUS), Dyax Corp (DYAX) Highlighted as Speculative Takeover Plays
October 12, 2015 12:06 PM EDTRadius Health (NASDAQ: RDUS) and Dyax Corp (NASDAQ: DYAX) highlighted as a potential takeover targets on... More
Radius Health (RDUS) Presents Positive Phase 3 Data from ACTIVE Trial at ASBMR Meeting
October 12, 2015 6:51 AM EDTRadius Health, Inc. (Nasdaq: RDUS) announces positive top-line data from the Phase 3 ACTIVE (Abaloparatide Comparator Trial InVertebral Endpoints) trial, which showed that women with postmenopausal osteoporosis (PMO) who received 18 months of daily abaloparatide (ABL) subcutaneous (SC) injection experienced a 70 percent reduction in the incidence of major osteoporotic fractures compared to placebo. Responder analysis showed greater increases in bone mineral density (BMD) at three combined anatomical sites (total hip, femoral neck and lumbar spine) compared to placebo or teriparatide (TPTD) at 6, 12 and 18 months. These results, along with positive pharmacokinetic data from a study evaluating the ABL... More
